Jennison Associates
AIMT

Jennison Associates’s Aimmune Therapeutics AIMT Stock Holding History

Jennison Associates’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-388,458
Closed -$9.29M – 709
2018
Q4 		$9.29M Sell
388,458
-44,518
-10% -$1.15M 0.01% 442
2018
Q3 		$11.8M Buy
432,976
+3,442
+0.8% +$97.4K 0.01% 456
2018
Q2 		$11.6M Buy
429,534
+7,668
+2% +$235K 0.01% 458
2018
Q1 		$13.4M Buy
+421,866
New +$14.8M 0.01% 436
2015
Q4 		– Sell
-200,503
Closed -$5.08M – 759
2015
Q3 		$5.08M Buy
+200,503
New +$4.69M 0.01% 541

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Jennison Associates's AIMT Position: Q1 2019 in Review

Jennison Associates sold out of Aimmune Therapeutics (AIMT) in Q1 2019, closing a stake of 388,458 shares — an estimated $9.29M sold.

Jennison Associates first reported a position in AIMT in Q3 2015 and held it in 5 quarters. The position peaked at $13.4M in Q1 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q1 2019.

  • Jennison Associates reported no remaining Aimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Jennison Associates sold 388,458 Aimmune Therapeutics shares in Q1 2019, an estimated $9.29M.
  • Jennison Associates first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 5 quarters.
  • Jennison Associates's Aimmune Therapeutics position peaked at $13.4M in Q1 2018.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2019.

Based on Jennison Associates's 13F filing for Q1 2019, filed 10 May 2019.